Patient-Reported Outcomes Data on SUBLOCADE™ (Buprenorphine Extended-Release) Injection to be Presented as Late-Breaker at American Society of Addiction Medicine (ASAM) 49th Annual Conference

SLOUGH, United Kingdom and RICHMOND, Va., April 13, 2018 /PRNewswire/ — Indivior PLC (LON: INDV) today announced the presentation of results from RB-US-13-0003, a study which evaluated long-term treatment with once-monthly SUBLOCADE™ (buprenorphine extended-release) injection for…

Share this post